中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2011年
11期
847-849
,共3页
肺肿瘤%癌胚抗原%细胞角蛋白片段19%诊断
肺腫瘤%癌胚抗原%細胞角蛋白片段19%診斷
폐종류%암배항원%세포각단백편단19%진단
Lung neoplssms%Carcinoembryonic antigen%Cytokeratin-19-frngments%Diagnosis
目的 探讨血清癌胚抗原(CEA)和细胞角蛋白片段19( CYFRA21-1)检测对肺癌的诊断价值.方法 采用电化学发光法对102例肺癌患者、78例肺部良性病患者和104例健康人血清进行分析,检测CEA和CYFRA21-1水平.结果 肺癌组患者血清中CEA水平及阳性率[(25.77±15.34) ng/ml,47.1％]均明显高于肺良性病组[(4.67±2.21)ml,7.7％]和健康组[(3.98±3.00)ng/ml,3.8％],差异有统计学意义(P＜0.05).肺癌组患者血清中CYFRA21-1水平及阳性率[(14.08±8.34)ng/ml,62.7％]也同样高于肺良性病组[(3.27±2.87)ml,7.7％]和健康组[(2.69±2.02)ng/ml,3.8％],差异有统计学意义(P＜0.05),而良性病组和健康组间差异无统计学意义(P＞0.05).肺癌组患者经TNM分期后,随着肿瘤分期级别的升高,CEA水平[Ⅱ～Ⅳ期分别为(17.78±8.71)ng/ml、(25.84±7.34)ng/ml和(34.85±6.99) ng/ml]和CYFRA21-1水平[Ⅱ～Ⅳ期分别为(10.05±6.76)ng/ml、(15.93±6.66) ng/ml和(22.78±4.12)ng/ml]也升高.CEA和CYFRA21-1联合检测后,灵敏度增高,特异度降低,准确率基本不变.结论 CEA和CYFRA21-1对肺癌有一定的辅助诊断价值,并且对肺癌的分期有一定诊断价值,联合检测可提高对肺癌的阳性诊断.
目的 探討血清癌胚抗原(CEA)和細胞角蛋白片段19( CYFRA21-1)檢測對肺癌的診斷價值.方法 採用電化學髮光法對102例肺癌患者、78例肺部良性病患者和104例健康人血清進行分析,檢測CEA和CYFRA21-1水平.結果 肺癌組患者血清中CEA水平及暘性率[(25.77±15.34) ng/ml,47.1％]均明顯高于肺良性病組[(4.67±2.21)ml,7.7％]和健康組[(3.98±3.00)ng/ml,3.8％],差異有統計學意義(P＜0.05).肺癌組患者血清中CYFRA21-1水平及暘性率[(14.08±8.34)ng/ml,62.7％]也同樣高于肺良性病組[(3.27±2.87)ml,7.7％]和健康組[(2.69±2.02)ng/ml,3.8％],差異有統計學意義(P＜0.05),而良性病組和健康組間差異無統計學意義(P＞0.05).肺癌組患者經TNM分期後,隨著腫瘤分期級彆的升高,CEA水平[Ⅱ～Ⅳ期分彆為(17.78±8.71)ng/ml、(25.84±7.34)ng/ml和(34.85±6.99) ng/ml]和CYFRA21-1水平[Ⅱ～Ⅳ期分彆為(10.05±6.76)ng/ml、(15.93±6.66) ng/ml和(22.78±4.12)ng/ml]也升高.CEA和CYFRA21-1聯閤檢測後,靈敏度增高,特異度降低,準確率基本不變.結論 CEA和CYFRA21-1對肺癌有一定的輔助診斷價值,併且對肺癌的分期有一定診斷價值,聯閤檢測可提高對肺癌的暘性診斷.
목적 탐토혈청암배항원(CEA)화세포각단백편단19( CYFRA21-1)검측대폐암적진단개치.방법 채용전화학발광법대102례폐암환자、78례폐부량성병환자화104례건강인혈청진행분석,검측CEA화CYFRA21-1수평.결과 폐암조환자혈청중CEA수평급양성솔[(25.77±15.34) ng/ml,47.1％]균명현고우폐량성병조[(4.67±2.21)ml,7.7％]화건강조[(3.98±3.00)ng/ml,3.8％],차이유통계학의의(P＜0.05).폐암조환자혈청중CYFRA21-1수평급양성솔[(14.08±8.34)ng/ml,62.7％]야동양고우폐량성병조[(3.27±2.87)ml,7.7％]화건강조[(2.69±2.02)ng/ml,3.8％],차이유통계학의의(P＜0.05),이량성병조화건강조간차이무통계학의의(P＞0.05).폐암조환자경TNM분기후,수착종류분기급별적승고,CEA수평[Ⅱ～Ⅳ기분별위(17.78±8.71)ng/ml、(25.84±7.34)ng/ml화(34.85±6.99) ng/ml]화CYFRA21-1수평[Ⅱ～Ⅳ기분별위(10.05±6.76)ng/ml、(15.93±6.66) ng/ml화(22.78±4.12)ng/ml]야승고.CEA화CYFRA21-1연합검측후,령민도증고,특이도강저,준학솔기본불변.결론 CEA화CYFRA21-1대폐암유일정적보조진단개치,병차대폐암적분기유일정진단개치,연합검측가제고대폐암적양성진단.
Objective To explore the diagnostic value of carcinoembryonic antigen (CEA) and cytokeratin-19-fragment (CYFRA21-1) in lung cancer patients.Methods The levels of serum CEA and CYFRA21-1 were measured in 102 patients with lung cancer,45 patients with benign lung disease and 36 health controls by electrochemiluminescence.Results The level of serum CEA and positive rate [(25.77 ±15.34) ng/ml,47.1％]were significantly higher in the lung cancer group than that in the benign lung disease group [(4.67 ±2.21)ml,7.7％; P＜0.05]and controls [(3.98 ±3.00) ng/ml,3.8％; P＜0.05 ],The level of serum CYFRA21-1 and positive rate [( 14.08 ± 8.34) ng/ml,62.7％]were also significantly higher in the lung cancer group than that in the benign lung disease group [(3.27 ± 2.87 ) ml,7.7％ ; P＜0.05]and controls [(2.69 ±2.02 ng/ml,3.8％ ; P＜0.05].The difference of level of CEA and CYFRA21-1 between the benign lung disease group and controls was statistically not significant (P ＞0.05).Both tumor markers were increased to a different degree in the lung cancer patients at various TNM stages [(CEA:stage Ⅱ (17.78 ±8.71) ng/ml,stage Ⅲ (25.84±7.34) ng/ml,stage Ⅳ (34.85 ±6.99)ng/ml; and CYFRA21-1:stage Ⅱ (10.05 ±6.76) ng/ml,stage Ⅲ (15.93 ±6.66) ng/ml,stage Ⅳ (22.78 ±4.12) ng/ml].Combined use of both makers showed a significant higher sensitivity (77.5％ vs.47.1％,62.8％ ),but reduced specificity (86.8％ vs.94.0％,95.6％ ),and not significantly changed accuracy (83.5％ vs.77.1％,83.8％ ) in the diagnosis of lung cancer.Conclusions CEA and CYFRA21-1 employed separately are helpful in the diagnosis of lung cancer.Combined detection of these two tumor markers can improve the positivity for diagnosis of lung cancer.
